Lung Cancer

Phase II study of 1L pembrolizumab in pts ≥ age 70 with PDL1+ NSCLC by @NadalErnest and @gecp_org now @LungCaJournal. 1Y OS rate 62% with mOS 19.2m. Confirms expectations, helpful to have prospective data. Age should not deter proper therapy. https://t.co/SqLywYzNK1 (@StephenVLiu)

Excited to see the latest @charlesrudin lab paper published in @ScienceTM: "Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers". #lungcancer #prostatecancer #SCLC #lineageplasticity https://t.co/sKHYNaave7 (@AlvaroQuintanal)

7/7 #TumorBoardTuesday Thurs Case🎀 🙏Careful discussion & individualized care, IO can be considered in neoadj setting for pts w autoimmune dz 🤔Better biomarkers 🎯 IO in future? 📅08.08: @MMarmarelis @norataranto explore tx after progression on Osimertinib in #EGFR m #NSCLC! (@JohnEbbenMDPhD)

Analysis of CROWN data (1L lorlatinib vs crizotinib) in #ALK NSCLC by EML4-ALK fusion variant and TP53 status @JTOonline. Given the clear biologic differences between variants (v3 vs others), I think it's time to stratify by variant and tailor strategies. https://t.co/iqJzIc5KEe (@StephenVLiu)

Delighted to discuss all things #BRAF on @BTOGORG podcast with @tnewsomdavis Highlighting what is known about the classes of BRAF mtn by @IbiayiMD& others, pivotal studies on BRAF/MEKi by @dplanchard @RielyMD, & use of IO @myESMO @IASLC @CancerCentreIre @IrishLungCancer #LCSM (@DrJNaidoo)

⏳ ONLY 2 weeks left to submit your abstract for the #EGFRSummit! DEADLINE to submit is Aug 18, don’t miss your opportunity & SUBMIT TODAY ➡️https://t.co/vNTrKAFBUg @jillfeldman4 @ivybelkins @ZPiotrowskaMD @egfrresisters @CEC_onc #LCSM #EGFR (@EGFRSummit)

WATCH: Expert oncologists reflect on the state of molecular testing in NSCLC and how it informs the management of patients with uncommon EGFR mutations. @benlevylungdoc @hopkinskimmel @UMiamiHealth #lungcancer https://t.co/vp5pIxGdHx (@OncLive)

#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)

In #clinicaltrial EA5161, investigators at are testing a new treatment approach for patients with #NSCLC w/ EGFR ex20-ins mutations. For more: https://t.co/pwy12PyvBr cc: @ZPiotrowskaMD, @LeciaSequist (@eaonc)

Delighted to share our latest paper on the mechanistic modeling of disease progression in EGFR-mutant lung adenocarcinoma: https://t.co/dsB0zfo9rc A special thanks to @MDuruisseaux & to all co-authors from @novadiscovery , @JanssenFRA. (@Claudio_MonT_s)

Choose your player! Drs. @SusanScottMD and @Joshua_Reuss will face off at #DCLung23 on whether STK11/KEAP1 mutations should influence 1L NSCLC treatment. Visit us in downtown DC on Saturday, October 7, 2023 to vote! Full agenda registration at: https://t.co/rJa81GX23a (@StephenVLiu)

Join us for this fun + inspiring “thinktank” to study #EGFR-mutant #lungcancer with a great community! Meet the incredible @jillfeldman4 + @ivybelkins! Link for abstract submission below. Deadline 8/18. #hemeoncfellows @OncoAlert #LCSM @EGFRResisters @EGFRSummit https://t.co/SiobKVyQKA (@christine_lovly)

@ALKLungCancer @EGFRResisters @lcfamerica @KRASKickers @brownbeansprout @jillfeldman4 @bjork5 @AboutLungCancer @LungCancerFaces @chrisdraft @ivybelkin @LungCancerRx @LungCancerEu @IASLC @LUNGFORCE @lcrf_org @LungAssociation @ALKPositiveinc (@RManochakian)

@ClaudioVladmir comenta estudo publicado online no Lung Cancer Journal que mostrou que a superexpressão de VEGFR2 foi independentemente associada com maior SG e maior SLP em pacientes com mesotelioma pleural - https://t.co/rulqlKcp5f @acccancercenter #MESOTELIOMA #ONCONEWS (@PortalOnconews)

Mail out lung cancer tests then. CyPath Lung will end the stigma and excuses. You spend a few minutes for a few days at home coughing to clear your lungs, and that will tell you with high accuracy whether you have #lungcancer. (@DrAaronThomason)

🚨 Time is Running out! Submitted your abstract for the #EGFRSummit! Don't let this opportunity slip away to 🚀your career as a #LungCancer researcher. The deadline is Aug 18➡️https://t.co/vNTrKAFBUg @egfrresisters @CEC_onc @jillfeldman4 @ivybelkins @ZPiotrowskaMD #LCSM #EGFR (@EGFRSummit)

New pub in ⁦@NatureCancer⁩: ALK peptide #vaccine strategy - developed by ⁦@chiarlelab⁩ + ⁦@DrMarkAwad⁩. Excited to see this strategy come into the clinic in the future! #LCSM ⁦@ALKPositiveinc⁩ ⁦@OncoAlert⁩ ⁦@LUNGevity⁩ https://t.co/q2Hc0pdo1b (@christine_lovly)

.@LudaBazhenovaMD, of @UCSDHealth, covered treatment and resistance with KRAS G12C inhibitors in NSCLC and highlighted MRTX1133 and RAS(ON), both KRAS G12D inhibitors. Still early stages but potential activity with RAS(ON) inhibitors in KRAS G12C-resistant disease #ILCC #lcsm (@OncLive)

“Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer” presented by Dr Roy S. Herbst and colleagues at the 2023 ASCO Annual Meeting https://t.co/gK0miTQZc6 @DrRoyHerbstYale @ASCO #ASCO23 (@clinadvances)

ICYMI: The TIGIT inhibitor domvanalimab & the A2R antagonist etrumadenant enhances the clinical activity of the PD-1 inhibitor zimberelimab when administered as triplet therapy in pts w/ PD-L1–high, metastatic NSCLC. @MLJohnsonMD2 @SarahCannonDocs #lcsm https://t.co/z5dxHeQf1S (@OncLive)

Should you test for EGFR exon 20 and NRG1 with DNA- or RNA-based NGS? Check out https://t.co/NFJ4GmvKuu to hear from @EdgardoSantosMD, of @FLASCO_ORG, #ILCC #lcsm #gotoPER @FloridaAtlantic (@OncLive)

Dr. @DDoroshow discusses RET fusions in NSCLC at #ILCC23 @gotoPER @MountSinaiNYC (@NarjustFlorezMD)

What are you looking forward to most at #EGFRSummit? Submit before Aug 18 & unlock new opportunities in your #LungCancer #Research career ➡️ https://t.co/vNTrKAG9JO @jillfeldman4 @ivybelkins @ZPiotrowskaMD @egfrresisters @CEC_onc #LCSM #EGFR (@EGFRSummit)

Learn what's new in RET-positive lung cancer from RET-expert @alexdrilon ! Click to RSVP. https://t.co/B0cTGpCuz2 (@RETpositive)

A multiD intervention (radiology, pathology, pharmacy, & oncology) ⬇️⬇️ time to start osimertinib for pts with #EGFR-mutant #NSCLC (5 vs 23 days) by directly analyzing frozen tissue & engaging pharmacy early: https://t.co/FHkNGChqVK #LungCancer #lcsm @IbiayiMD (@JCOOP_ASCO)

Congrats to @APassaroMD & authors: https://t.co/xRnnGprcc9 Most oncologists handling #EGFR #Exon20 avoid IO in 1L. #PAPILLON & #EXCLAIM2 Ph 3's have the correct comparator: the doublet! Please all: Let us know if you have exceptional IO responders w/any EGFR ex 20 variant. #LCSM https://t.co/8q2dn61rH5 (@Exon20Group)

#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)

🌟 Unlock new possibilities in #LungCancer #Research and shape your professional journey at the #EGFRSummit. Don't miss the chance to submit your abstracts by Aug 18➡️https://t.co/vNTrKAFBUg @jillfeldman4 @ivybelkins @ZPiotrowskaMD @egfrresisters @CEC_onc #LCSM #EGFR (@EGFRSummit)

🎯 Calling all #LungCancer researchers! Submit your abstract for #EGFRSummit! 🔬Elevate your #Research skills 🔍Review peers' work 🔥Ignite your career DEADLINE Aug 18➡️https://t.co/vNTrKAFBUg @jillfeldman4 @ivybelkins @ZPiotrowskaMD @egfrresisters @CEC_onc #LCSM #EGFR (@EGFRSummit)

Paper published 🤩📄 Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Go and CHECK IT OUT! 🧬 Read 👉🏻 https://t.co/tKRM2KgL0c Team effort 🤩🫁 👨🏻‍⚕️@Ecaballep 👩🏽‍⚕️@YanHernandezP 👩🏻‍⚕️@maritza_rramos 👨🏻‍⚕️@AndresFCardonaZ 👨🏻‍⚕️ @ogarrieta #KRAS #NSCLC #outcome #UFOT #INCan (@UToracica)

Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Our cohort shows 15.6% mKRAS (32, 32, 14% for G12C, G12D and G12V), G12D is associated with female and a lower smoking rate (pack/year). @incanMX @AndresFCardonaZ @Ecaballep https://t.co/YVgxHYVNAZ (@ogarrieta)

🧬🎯 promising phase 1/2 vs EGFR ex20ins 🤞 accompanying editorial from @CharuAggarwalMD is 👌 Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Ex20ins https://t.co/bhscPeHnZn (@forbesygordi)

Assessment of Tumor Mutational Burden [#TMB] and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy [May 2, 2023] @CharuAggarwalMD et al. @JPatelMD @JAMANetworkOpen https://t.co/26qHIi8CzA #ImmunoOnc #PrecisionMedicine #lcsm @TempusLabs (@mtmdphd)

Is anyone studying SBRT + IO? Encouraged by the recent success of SBRT + atezo in early stage NSCLC- but not sure if the same biological rationale is present here (maybe in later line or high TMB NETs) @RachelRiechelm2 (@JohnEbbenMDPhD)

Yes. This is not even that. This is lorlatinib for ped brain cancer prior to resection. And mutations not given. Lorlatinib has more data for nsclc w alk and brain Mets. (@VPrasadMDMPH)

This is lorlatinib for pediatric brain cancer (at least that is my impression) neo adjuvant. We don't know the mutational profile of the child. I doubt any country in Europe would cover it. It's not lorlatinib for nsclc with alk. (@VPrasadMDMPH)

Honored to write an invited editorial on "Zipalertinib in EGFR Exon 20–Mutant NSCLC" - out now in @JCO_ASCO @ASCO @StephenVLiu - we discuss the role of novel TKIs, and drug development in this rare, but increasingly crowded space! Congrats to the authors on this important… https://t.co/q2gu83PHLN (@CharuAggarwalMD)

@AlastairGreyst2 My mum's scan results are back after having to PAY £9K every 3 weeks for ENHERTU for her lung cancer and it's WORKING. Why is this drug not available for all with the HER2? Can you help us push @NICEComms to fast-track this for more people? (@elliely39073921)

Life has been and will be tough for you Joshua. That’s unfortunate but necessary for the life of discovery. I’m Choosing not to prove 3 daily would have been better than 50 cigarettes to prevent lung cancer. Same goes for apoB. Darwin was right about your tribe son (@daedalus0101)

Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer - ⁦@JTOonline⁩ (N=46) ⬆️central obesity from 27-47% ➡️ as pts get treated for years, weight gain is a serious AE #lcsm ⁦@ALKPositiveinc⁩ ⁦ https://t.co/FJlfh8BgKv (@Latinamd)

A targeted therapy drug improved survival in pts w/ #lungcancer who have #EGFR mutations. PC3I's @CharuAggarwalMD provided input for @theNCI: “This confirms our practice to test for EGFR mutations and recommend adjuvant targeted therapy with osimertinib” https://t.co/O3AdUxmIdX (@PC3Innovation)

Join experts @MLJohnsonMD2, @EnriquetaFelip, & Prof. Hayashi and improve your understanding of the next wave of novel #ADCs and how to incorporate them into clinical practice and trials for patients with #NSCLC. 9/12 at 13:00 SGT during #WCLC23: https://t.co/atVNPESBDE #MedEd (@PeerView)